Empowering the Development of TCR-T and CAR-T Cells for Adoptive Cell Therapy

Join us for this live webinar, co-organized with our partner BPS Bioscience, to explore how their suite of innovative tools can support your CAR and TCR-T development projects.

What is this webinar about?

Adoptive cell immunotherapy leverages genetically engineered immune cells such as T cells that recognize specific antigens via T cell receptors (TCRs) or CARs (chimeric antigen receptor). When these receptors bind to target antigens present on the surface of cells of interest, they activate T cells, triggering an immune response that kills the cells. This approach allows for precision treatment by engineering T cells to target specific antigens.

This webinar will demonstrate the utility of a new suite of tools supporting CAR and TCR-T cell development projects, including primary human immune cells as well as cellular assays that provide essential biological evidence of target recognition, cell activation, and effector functions. In addition, novel tools were developed to support the screening of HLA alleles in TCR engineering projects.

Why should you attend?

1. Discover a powerful new suite of tools designed to support every step of CAR and TCR-T cell development.
2. Gain critical biological insights through cellular assays that demonstrate target recognition, T cell activation, and effector functions.
3. Work with ready-to-use primary human immune cells for more physiologically relevant results.
4. Leverage cutting-edge tools for HLA allele screening, essential for next-generation TCR engineering projects.

Who should attend?

• Researchers working on Immunotherapies, including CAR-T and TCR-T cells, interested in antigen recognition mechanisms and immune responses.
• Scientists in Cell and Gene Therapy, involved in the development of personalized therapies using genetically modified cells, developing and validating novel CAR or TCR constructs.
• Immunologists studying T cell biology, TCR-HLA interactions, or adaptive immune responses, looking at primary immune cells or functional assay platforms.
• Project Leaders developing new immunotherapies, proof-of-concept, functional validation stages, and looking for reliable tools to streamline screening and characterization workflows.
• Professionals in Cell Therapy Bioproduction working on the generation, handling, or expansion of human immune cells for therapeutic purposes.

Your webinar presenters

Discover our Latest Newsletter Addressed to Immuno-Oncology Researchers